Is treatment of feline hypertrophic cardiomyopathy based in science or faith? A survey of cardiologists and a literature search - PubMed (original) (raw)
Is treatment of feline hypertrophic cardiomyopathy based in science or faith? A survey of cardiologists and a literature search
Mark Rishniw et al. J Feline Med Surg. 2011 Jul.
Abstract
Practical relevance: Feline hypertrophic cardiomyopathy (HCM) is the most common cardiac disease of cats. Treatment of HCM is usually directed at controlling signs of congestive heart failure (CHF), preventing occurrence or recurrence of systemic thromboembolism or delaying/preventing/reversing progression of subclinical disease.
Study objective and design: Despite the laudable goals of therapy, however, little objective evidence supporting therapeutic decisions has been published. We, therefore, hypothesized that cardiologists base their treatment strategies on information other than published clinically relevant science. To gain insight into therapeutic decisions that cardiologists and clinicians with an interest in cardiology (n=99) make for cats with HCM, and on what information they base these decisions, we presented participants with, and asked them to select therapy for, 12 hypothetical scenarios of HCM (± CHF). Responses and justifications for treatment choices were compiled and compared with the results of a comprehensive literature search for published information about treatment of feline HCM.
Findings: Evaluation of the therapeutic strategies chosen for these hypothetical cases of HCM suggests that cardiologists or clinicians with a strong interest in cardiology often prescribe treatments knowing that little documented evidence supports their decisions.
Copyright © 2011 ISFM and AAFP. Published by Elsevier Ltd. All rights reserved.
Figures
FIG 1
(a) Intent to alter primary disease progression or to treat congestive heart failure (CHF). Collated responses were restricted to drugs or interventions that are not obviously antithrombotic or anticoagulant. (b) Intent to reduce risk of occurrence of aortic thromboembolism (ATE). Collated responses were restricted to clopidogrel, aspirin, low molecular weight heparin (LMWH) and heparin. In (a) and (b) cardiologist respondents are represented by the pink bars, non-cardiologist respondents by the black bars. (c) Use of clopidogrel or LMWH
FIG 2
(a) Number of different treatment combinations adopted by respondents for each scenario. (b) Percentage of respondents prescribing three or more medications to patients with each scenario. CHF = congestive heart failure
FIG 3
Cardiologist respondents are represented by the pink bars, non-cardiologist respondents by the black bars. Numbers above bars represent the left ventricular outflow tract (LVOT) velocity (expressed in m/s) associated with LVOT obstruction presented in that particular scenario. CHF = congestive heart failure
FIG 4
(a) Angiotensin-converting enzyme inhibitor (ACEI) use increases with increasing severity of hypertrophic cardiomyopathy (HCM). (b) Diltiazem use is substantially lower than ACEI use and is inversely correlated with β-blocker use. Cardiologist respondents are represented by the pink bars, non-cardiologist respondents by the black bars
Comment in
- Science, faith or something else?
Rosenthal RC. Rosenthal RC. J Feline Med Surg. 2011 Jul;13(7):485-6. doi: 10.1016/j.jfms.2011.05.004. J Feline Med Surg. 2011. PMID: 21704897 Free PMC article. No abstract available.
Similar articles
- The Feline Cardiomyopathies: 2. Hypertrophic cardiomyopathy.
Kittleson MD, Côté E. Kittleson MD, et al. J Feline Med Surg. 2021 Nov;23(11):1028-1051. doi: 10.1177/1098612X211020162. J Feline Med Surg. 2021. PMID: 34693811 Free PMC article. - Therapy of feline hypertrophic cardiomyopathy.
Rush JE. Rush JE. Vet Clin North Am Small Anim Pract. 1998 Nov;28(6):1459-79, ix. doi: 10.1016/s0195-5616(98)50132-5. Vet Clin North Am Small Anim Pract. 1998. PMID: 10098248 Review. - Feline hypertrophic cardiomyopathy: an update.
Baty CJ. Baty CJ. Vet Clin North Am Small Anim Pract. 2004 Sep;34(5):1227-34. doi: 10.1016/j.cvsm.2004.06.005. Vet Clin North Am Small Anim Pract. 2004. PMID: 15325479 Review. - Evaluation of red blood cell distribution width in cats with hypertrophic cardiomyopathy.
Stanzani G, Cowlam R, English K, Connolly DJ. Stanzani G, et al. J Vet Cardiol. 2015 Dec;17 Suppl 1:S233-43. doi: 10.1016/j.jvc.2015.09.001. J Vet Cardiol. 2015. PMID: 26776582 - Plasma growth differentiation factors 8 and 11 levels in cats with congestive heart failure secondary to hypertrophic cardiomyopathy.
Yang VK, Rush JE, Bhasin S, Wagers AJ, Lee RT. Yang VK, et al. J Vet Cardiol. 2019 Oct;25:41-51. doi: 10.1016/j.jvc.2019.08.002. Epub 2019 Sep 1. J Vet Cardiol. 2019. PMID: 31568985 Free PMC article.
Cited by
- Association of diet with left ventricular wall thickness, troponin I and IGF-1 in cats with subclinical hypertrophic cardiomyopathy.
van Hoek I, Hodgkiss-Geere H, Bode EF, Hamilton-Elliott J, Mõtsküla P, Palermo V, Pereira YM, Culshaw GJ, Laxalde J, Dukes-McEwan J. van Hoek I, et al. J Vet Intern Med. 2020 Nov;34(6):2197-2210. doi: 10.1111/jvim.15925. Epub 2020 Oct 29. J Vet Intern Med. 2020. PMID: 33118674 Free PMC article. - Antioxidant defence and oxidative stress markers in cats with asymptomatic and symptomatic hypertrophic cardiomyopathy: a pilot study.
Michałek M, Tabiś A, Pasławska U, Noszczyk-Nowak A. Michałek M, et al. BMC Vet Res. 2020 Jan 30;16(1):26. doi: 10.1186/s12917-020-2256-3. BMC Vet Res. 2020. PMID: 32000761 Free PMC article. - Evaluation of benazepril in cats with heart disease in a prospective, randomized, blinded, placebo-controlled clinical trial.
King JN, Martin M, Chetboul V, Ferasin L, French AT, Strehlau G, Seewald W, Smith SGW, Swift ST, Roberts SL, Harvey AM, Little CJL, Caney SMA, Simpson KE, Sparkes AH, Mardell EJ, Bomassi E, Muller C, Sauvage JP, Diquélou A, Schneider MA, Brown LJ, Clarke DD, Rousselot JF. King JN, et al. J Vet Intern Med. 2019 Nov;33(6):2559-2571. doi: 10.1111/jvim.15572. Epub 2019 Sep 27. J Vet Intern Med. 2019. PMID: 31560137 Free PMC article. - Variation in the Reported Management of Canine Prolapsed Nictitans Gland and Feline Herpetic Keratitis.
White CN, Jones G, Baker S, Dean RS, Brennan ML. White CN, et al. Vet Sci. 2018 Jun 1;5(2):54. doi: 10.3390/vetsci5020054. Vet Sci. 2018. PMID: 29865183 Free PMC article.
References
- . Liu SK, Tilley LP, Lord PF. Feline cardiomyopathy. Recent Adv Stud Cardiac Struct Metab 1975; 10: 627–40. - PubMed
- . Paige CF, Abbott JA, Elvinger F, Pyle RL. Prevalence of cardiomyopathy in apparently healthy cats. J Am Vet Med Assoc 2009; 234: 1398–403. - PubMed
- . Coté E, Manning AM, Emerson D, Laste NJ, Malakoff RL, Harpster NK. Assessment of the prevalence of heart murmurs in overtly healthy cats. J Am Vet Med Assoc 2004; 225: 384–88. - PubMed
- . Rush JE, Freeman LM, Fenollosa NK, Brown DJ. Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990–1999). J Am Vet Med Assoc 2002; 220: 202–7. - PubMed
- . Atkins CE, Gallo AM, Kurzman ID, Cowen P. Risk factors, clinical signs, and survival in cats with a clinical diagnosis of idiopathic hypertrophic cardiomyopathy: 74 cases (1985–1989). J Am Vet Med Assoc 1992; 201: 613–18. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous